A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Descamps, G, Gomez-Bougie, P, Venot, C, Moreau, P, Bataille, R, Amiot, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634719/
https://www.ncbi.nlm.nih.gov/pubmed/19165200
http://dx.doi.org/10.1038/sj.bjc.6604839
Descripción
Sumario:The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14).

Ejemplares similares